0001209191-21-059986.txt : 20211007
0001209191-21-059986.hdr.sgml : 20211007
20211007190312
ACCESSION NUMBER: 0001209191-21-059986
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210927
FILED AS OF DATE: 20211007
DATE AS OF CHANGE: 20211007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moran Michael Shawn
CENTRAL INDEX KEY: 0001886788
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36306
FILM NUMBER: 211313432
MAIL ADDRESS:
STREET 1: C/O EAGLE PHARMACEUTICALS, INC.
STREET 2: 50 TICE BLVD., SUITE 315
CITY: WOODCLIFF
STATE: NJ
ZIP: 07677
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000827871
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 TICE BOULEVARD, SUITE 315
CITY: WOODCLIFF LAKE
STATE: NJ
ZIP: 07677
BUSINESS PHONE: 201-326-5300
MAIL ADDRESS:
STREET 1: 50 TICE BOULEVARD, SUITE 315
CITY: WOODCLIFF LAKE
STATE: NJ
ZIP: 07677
FORMER COMPANY:
FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19880120
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-09-27
0
0000827871
EAGLE PHARMACEUTICALS, INC.
EGRX
0001886788
Moran Michael Shawn
C/O EAGLE PHARMACEUTICALS, INC.
50 TICE BLVD., SUITE 315
WOODCLIFF LAKE
NJ
07677
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
24268
D
Employee Stock Option (right to buy)
66.32
2026-01-27
Common Stock
10000
D
Employee Stock Option (right to buy)
84.92
2027-01-03
Common Stock
27000
D
Employee Stock Option (right to buy)
59.14
2028-01-06
Common Stock
5000
D
Employee Stock Option (right to buy)
41.37
2029-01-29
Common Stock
1594
D
Employee Stock Option (right to buy)
59.79
2030-01-05
Common Stock
37500
D
20,828 of the shares represent restricted stock units ("RSU") awards. The RSUs shall vest: 253 RSUs on January 7, 2022; 563 RSUs on January 29, 2022; 562 RSUs on January 29, 2023; 3,750 RSUs on each of January 5, 2022, January 5, 2023 and January 5, 2024; and 2,050 RSUs on each of February 2, 2022, February 2, 2023, February 2, 2024 and February 2, 2025, subject to the Reporting Person's continuous service through each vesting date.
The options are fully vested and exercisable.
One fourth (1/4th) of the shares underlying the option vested on January 7, 2019, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.
The option grant was initially 4,500 shares of which one fourth (1/4th) of the shares underlying the option vested on January 29, 2020, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.
One fourth (1/4th) of the shares underlying the option vested on January 5, 2021, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.
/s/ Brian Cahill, Attorney-in-Fact
2021-10-07
EX-24.3_1012290
2
poa.txt
POA DOCUMENT
Exhibit 24
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Brian Cahill and Ryan Debski of Eagle Pharmaceuticals, Inc. (the
"Company") and each of Marc Recht (attorney), Paul Alexander (attorney),
Jonathan Robertson (attorney), Julie Allison Weltman (attorney), and Jason Minio
(senior paralegal) of the law firm Cooley LLP ("Cooley"), signing individually,
the undersigned's true and lawful attorney-in fact and agent to:
(1) prepare, execute on behalf of the undersigned, and submit to the U.S.
Securities and Exchange Commission (the "SEC") any documents necessary or
advisable to obtain EDGAR access codes or make any updates to the undersigned's
EDGAR access codes once obtained, enabling the undersigned to make electronic
filings of reports with the SEC;
(2) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(3) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the SEC and any stock exchange or similar authority;
and
(4) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company or by Cooley, as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 4th day of October 2021.
/s/ Michael Moran
Michael Moran